Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
ABUS Q2-25 showed a sharp swing to profitability as one-time license revenue and deep cost cuts outweighed lower investment income. Total revenue rose to $10.7 m from $1.7 m a year earlier, driven mainly by recognition of $9.6 m in deferred revenue after the June termination of the Qilu partnership, which also returns worldwide rights to imdusiran. Non-cash royalty revenue from Alnylam’s ONPATTRO contributed $0.5 m.
Operating expenses fell 60% YoY to $9.3 m following a 57% workforce reduction, facility exit and R&D scale-back; Q1 restructuring charges totaled $12.4 m. As a result, operating income reached $1.5 m versus a $21.6 m loss last year, and net income reached $2.5 m ($0.01/share) versus a $19.8 m loss. For the six months, the company still posted a $22.0 m loss, but cash burn declined (operating cash outflow $29.1 m vs $33.8 m).
Cash, cash equivalents and short-term securities were $98.1 m at 30-Jun-25 (down from $122.6 m at year-end) with no debt; management expects runway of ≥12 months. Total assets fell to $103.3 m, liabilities to $20.3 m and equity to $83.0 m. Contingent consideration stands at $10.8 m and the liability from royalty-sale to OMERS declined to $3.9 m.
Key catalysts include Phase 2 data from imdusiran combinations, ongoing Phase 1a/1b dosing of oral PD-L1 inhibitor AB-101, and patent litigation milestones against Moderna and Pfizer/BioNTech (trial in Mar-26). Cost-control measures and regained global rights position Arbutus for partnering, but termination of Qilu removes future milestone streams.
Arbutus Biopharma (NASDAQ:ABUS) announced the termination of its technology transfer and license agreement with Qilu Pharmaceutical Co., Ltd. The agreement, originally established in December 2021, granted Qilu exclusive rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan.
The mutual termination, effective June 20, 2025, involves no financial payments and results in all rights for imdusiran in Greater China and Taiwan reverting to Arbutus. This decision aligns with Qilu's pipeline reprioritization and Arbutus's strategic focus on efficient pipeline advancement.